HMVP与MVP方案治疗晚期非小细胞肺癌的临床研究  

Clinica study comparing HMVP and MVP regimens in the treatment of advanced non-small cell lung cancer

作　　者：高建飞[1] 李长生[2] 杜光祖[1] 章必成[1] 

机构地区：[1]广州军区武汉总医院肿瘤血液科,湖北武汉430070 [2]武汉大学人民医院呼吸内科,湖北武汉430060

出　　处：《中国癌症杂志》2004年第3期277-278,281,共3页China Oncology

摘　　要：目的 :旨在观察羟基喜树碱 (hydroxycamptothecin ,HCPT)联合丝裂霉素 (mitomycin ,MMC)、长春花碱酰胺 (vindesine ,VDS)和顺铂 (cisplatin ,DDP)组成的HMVP和MVP方案治疗晚期NSCLC的近期、远期疗效和毒副反应。方法 :将 90例晚期NSCLC患者随机分为HMVP组 (4 6例 )与MVP组 (4 4例 ) ,观察两组的近期及远期疗效、毒副反应和生存情况。结果 :HMVP和MVP有效率分别为 39.5 4 %和 35 .5 7% ,两组之间无显著性差异 (P >0 .0 5 ) ;两组的中位缓解期、中位生存期、一年及二年生存率亦无明显差异。两组的Ⅲ～Ⅳ度白细胞抑制率、Ⅲ～Ⅳ度血小板抑制率、Ⅲ～Ⅳ度恶心 /呕吐发生率、Ⅲ～Ⅳ度便秘发生率之间均无显著性差异 (P >0 .0 5 )。结论 :MVP方案治疗晚期NSCLC的疗效略低于HMVP方案 ,但后者未显示出明显的疗效优势 ,却可能增加白细胞抑制、恶心 /呕吐和便秘的发生率 ,也增加了患者的经济负担 ;Purpose:The objective of this article is to evaluate the response, toxicity and survival time of HMVP and MVP regimens in the treatment of advanced NSCLC. Methods:A total of 90 cases with advanced NSCLC was randomized into two groups: HMVP group [46 patients, hydroxycamptothecin (HCPT) 12 mg/m 2 from d1 to d5, mitomycin C (MMC) 6 mg/m 2 d1, vindesine (VDS) 2.5～3 mg/m 2 d1 and d8, cisplatin (DDP) 50 mg/m 2 d2 and d3], MVP group (44 patients, MMC, VDS and DDP were the same as HMVP group). Results:The response rates were 39.5%(17/43) and 35.6%(15/42) in the HMVP, and MVP group respectively, but no significant difference was detected between the groups (P>0.05). No significant differences were detected in the median time of remission, median survival time and 1-, 2-year survival rates between the groups. Moreover, no significant differences were detected in the grade Ⅲ～Ⅳ leukopenia, grade Ⅲ～Ⅳ thrombocytopenia, grade Ⅲ～Ⅳ nausea and vomiting and grade Ⅲ～Ⅳ constipation between the groups. Conclusions:The response rate of the MVP regimen is slightly lower than the HMVP regimen, but the HMVP regimen is not noticeably superior. It may increase the toxicity such as leukopenia, nausea/vomiting and constipation, as wellas being more expensive. In short, MVP regimen should be selected between the regimens in the chemotherapy of advanced NSCLC.

关 键 词：非小细胞肺癌 化学疗法 丝裂霉素 羟基喜树碱 长春地辛 顺铂 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]